Literature DB >> 32398704

Activity of regorafenib plus nivolumab.

Diana Romero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32398704     DOI： 10.1038/s41571-020-0389-8

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).

Authors:  Shota Fukuoka; Hiroki Hara; Naoki Takahashi; Takashi Kojima; Akihito Kawazoe; Masako Asayama; Takako Yoshii; Daisuke Kotani; Hitomi Tamura; Yuichi Mikamoto; Nami Hirano; Masashi Wakabayashi; Shogo Nomura; Akihiro Sato; Takeshi Kuwata; Yosuke Togashi; Hiroyoshi Nishikawa; Kohei Shitara
Journal:  J Clin Oncol       Date:  2020-04-28       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.